ART Advanced Research Technologies to Be Present at the Annual Meeting of the Society of Toxicology in Seattle, WA
March 17 2008 - 9:14AM
Marketwired
MONTREAL, CANADA (TSX: ARA), a Canadian medical device company
and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, will be exhibiting at the
Society of Toxicology (SOT) Annual Meeting, March 17-19, Seattle,
WA. ART will showcase its preclinical product offering, including
the Optix� MX2 optical imaging device and the Fenestra� line of
contrast agents for micro CT imaging at its booth (#1639) located
in the Exhibit Hall of the Washington State Convention and Trade
Center. In addition, Dr. Joanna Napp from the University of
Goettingen in Germany will be presenting recent research using the
Optix device in a pancreatic tumor mouse model, to evaluate novel
targeted tumor therapies by non-invasive time domain near infrared
imaging.
The Society of Toxicology (SOT) Annual Meeting is the largest
toxicology meeting and exhibition in the world, attracting
approximately 6,200 scientists from industry, academia, and
government. The program includes a plenary and other special
lectures, symposia, workshops, roundtable discussions, and platform
and poster presentations.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is used by industry and academic leaders worldwide. The
SoftScan� optical medical imaging device is designed to improve the
diagnosis and treatment of breast cancer. ART is commercializing
these products in a global strategic alliance with GE Healthcare, a
world leader in mammography and imaging. Finally, the Fenestra�
line of molecular imaging contrast products provide image
enhancement for a wide range of preclinical Micro CT applications
allowing scientists to see greater detail in their imaging studies,
with potential extension into other major imaging modalities. ART's
shares are listed on the TSX under the ticker symbol ARA. For more
information on ART, visit our website at www.art.ca .
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2006, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer 514-832-0777 jbedard@art.ca www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024